In recent years, non-viral methods for cell engineering have emerged as promising alternatives to viral transduction. Amongst the virus-free technologies, electroporation is considered the gold standard, with an increasing presence in clinical trials.

Learn about a next-generation large-scale electroporation platform and how it can be used for the efficient delivery of clinically relevant cargos into large volumes of T cells.

The expert panel will demonstrate how optimal parameters for cell handling established in small scale were successfully adapted to large-scale formats, enabling the efficient transfection of up to one billion cells. Join for a deep dive into scientific data sets focusing on gene editing tools such as CRISPR and transposon-based integration methods. 

Learning Objectives: 

1. How to achieve reliable, robust and efficient delivery of different cargo types from DNA and mRNA to complex, clinically relevant cargos for CRISPR knock-out/knock-in (RNPs) or transposon-based integration.

2. How to easily scale up of the cell engineering process to 1 billion T cells.

3. How the electroporation platform supports GMP manufacturing.